• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endocrinology, Diabetes & Metabolism >Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague‐Dawley rats
【24h】

Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague‐Dawley rats

机译：调查Aliskiren在糖尿病Sprague-Dawley大鼠中衰减神经性疼痛中的有益作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives Worldwide, diabetic neuropathy (DN) is a major complication of diabetes mellitus. The direct renin inhibitor aliskiren is recognized as a treatment for cardiovascular disease in diabetic patients, but little is known about its potential benefits in cases of diabetic neuropathy. Accordingly, we investigated the effects of aliskiren (ALIS) and gliclazide (GLZ) and their combination therapy on peripheral neuropathy in streptozotocin‐induced diabetic rats. Methods In total, 112 adult Sprague‐Dawley rats were used for this study. Diabetes was induced using streptozotocin (STZ), whereas the control group was treated with an equal volume of citrate buffer. The diabetic rats were divided randomly into six groups according to the proposed treatment regime: diabetic control (DC), gliclazide (GLZ), aliskiren (ALIS), ramipril (RAM), (GLZ?+?ALIS) and (GLZ?+?RAM). Behavioural responses to thermal (hot‐plate) and mechanical (tail‐pinch) pain were evaluated. After eight weeks of daily treatments, the animals were fasted and sacrificed. The blood samples were collected, with the serum separated and subjected to various biochemical and enzyme analyses so as to assess the effect of the treatments on diabetic peripheral neuropathy. Results After 8?weeks, aliskiren alone and in combination with gliclazide therapy had a significant effect ( P ?.001) in reducing blood glucose levels and showed increased hot‐plate and tail‐flick latencies compared with the diabetic control group. The threshold of mechanical hyperalgesia was also significantly elevated ( P ?.001). Conclusions/Interpretations These data suggest that either aliskerin alone or in combination with gliclazide can protect against the development and progression of diabetic neuropathy.
机译：全球目标，糖尿病神经病变（DN）是糖尿病糖尿病的主要复杂性。直接肾素抑制剂Aliskiren被认为是糖尿病患者心血管疾病的治疗，但在糖尿病神经病变的情况下对其潜在益处几乎是众所周知的。因此，我们研究了Aliskiren（ALIS）和Gliclazide（GLZ）的影响及其组合治疗链脲佐菌素诱导的糖尿病大鼠的周围神经病理。方法总共112种成人Sprague-Dawley大鼠用于本研究。使用链脲佐菌素（STZ）诱导糖尿病，而对照组用相等体积的柠檬酸盐缓冲液处理。根据拟议的治疗方案，随机分为六组糖尿病大鼠：糖尿病对照（DC），Gliclazide（Glz），Aliskiren（Alis），ramipril（RAM），（GLZ？+？ALIS）和（GLZ？+？内存）。评估对热（热板）和机械（尾夹）疼痛的行为响应。经过八周的日常治疗后，动物被禁食并处死。收集血清的血清分离并进行各种生化和酶分析，以评估治疗对糖尿病外周神经病变的影响。结果8？周，单独的Aliskiren与Gliclazide治疗结合在减少血糖水平时具有显着的影响（P <。001），并与糖尿病对照组相比，与糖尿病对照组相比显示出增加的热板和尾桨延迟。机械痛觉的阈值也显着升高（P <。001）。结论/解释这些数据表明，单人类单独或与Gliclazide组合可以防止糖尿病神经病变的发展和进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号